These findings are in line with a previous study showing a significant reduction in p21CIP1 protein expression levels in invasive breast cancer who received NAC regimens (docetaxel in combination with epirubicin) compared with the core biopsy specimens from same breast cancer patients before NAC [67]. This evidence concerns the gene CDKN1A and breast carcinoma.